UCB, a global biopharmaceutical company, is set to present 26 scientific abstracts at the International Epilepsy Congress in Lisbon, Portugal, from August 30 to September 3, 2025. This presentation highlights UCB’s commitment to advancing research and clinical care for individuals living with epilepsy, particularly focusing on developmental and epileptic encephalopathies (DEEs) such as Dravet syndrome and Lennox-Gastaut syndrome.
Among the key presentations is an open-label extension study of FINTEPLA (fenfluramine), which involved 412 patients with Dravet and Lennox-Gastaut syndromes. The study revealed no new safety concerns and emphasized long-term benefits for patients. This research underscores UCB’s dedication to enhancing treatment options for those affected by severe epileptic conditions.
Dimitrios Bourikas, Global Medical Head of DEE and Epilepsy at UCB, stated, “At UCB, we are committed to driving improvements in all aspects of care for people living with epilepsies and severe epileptic conditions.” He added that the data presented at the congress reflect UCB’s goal of addressing real-world patient needs through innovative solutions.
Key Findings and Insights
The findings to be presented include several important studies:
1. **Barriers to Diagnosis in Adults**: A qualitative study revealed significant diagnostic gaps in identifying DEEs in adults, despite advancements in pediatric care. Interviews with caregivers and healthcare professionals from the UK, Germany, France, and Spain highlighted that a confirmed diagnosis can improve quality of life and reduce hospitalization risks.
2. **Impact of Unpredictable Seizures**: A survey conducted among caregivers indicated that nearly half reported that disruptive seizures led to temporary losses in abilities, significantly affecting quality of life.
3. **Characterization of Prolonged Seizures**: Research characterizing experiences related to prolonged seizures noted substantial unmet needs and identified both short-term and long-term negative impacts on daily living for patients and caregivers.
4. **Seizure Pathways**: A study focused on the management of acute seizure emergencies found that improved outpatient guidelines could empower patients and caregivers, potentially reducing unnecessary escalation and hospital admissions.
5. **Acute Medication Landscape**: UCB conducted a global analysis of the availability and reimbursement of seizure medications for outpatient use. This analysis will aid in understanding the accessibility of treatments for patients worldwide.
UCB is also sponsoring a symposium titled “Time Matters in Developmental and Epileptic Encephalopathies,” which aims to enhance awareness of the broader impacts of DEEs in adulthood beyond seizure control. This session will focus on improving diagnosis and addressing barriers to care to drive better individual outcomes.
Future Directions
As UCB continues its research and development efforts, the company remains dedicated to deepening insights into epilepsy and its treatment. The findings presented at the International Epilepsy Congress will play a crucial role in shaping future protocols and improving care for those affected by these challenging conditions.
With approximately 9,000 employees in 40 countries and a revenue of €5.3 billion in 2023, UCB is positioned at the forefront of biopharmaceutical innovation. The company’s ongoing efforts to address the complexities of epilepsy treatment demonstrate a profound commitment to improving patient outcomes and quality of life.
For more information about UCB and its initiatives, visit their official website at www.ucb.com.
